# Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation

Study · id `cardio:ct-nct06791629` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06791629](<https://clinicaltrials.gov/study/NCT06791629>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06791629

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 700 participants.

## Technical summary

Registry record NCT06791629. Randomized; no masking; primary purpose treatment. Start 2025-02-15 (anticipated); primary completion 2026-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT06791629, source copy `cardio:ctgov-nct06791629-2025-01-24`, retrieved 2026-10-26)
- Planned start: 2025-02-15 (anticipated) (ClinicalTrials.gov record NCT06791629, source copy `cardio:ctgov-nct06791629-2025-01-24`, retrieved 2026-10-26)
- Primary completion: 2026-12-15 (anticipated) (ClinicalTrials.gov record NCT06791629, source copy `cardio:ctgov-nct06791629-2025-01-24`, retrieved 2026-10-26)
- Completion: 2027-02-15 (anticipated) (ClinicalTrials.gov record NCT06791629, source copy `cardio:ctgov-nct06791629-2025-01-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06791629, source copy `cardio:ctgov-nct06791629-2025-01-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06791629-2025-01-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation
- Acronym: PRAISE
- Condition: Persistent Atrial Fibrillation
- Condition: Radiofrequency Catheter Ablation
- Condition: Pulsed Field Ablation
- Intervention (Device): Pulsed Field Ablation
- Intervention (Device): Radiofrequency Ablation
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: cdc7ec2896d152f73738084bf4b044722ee986c3efffecbaf5937720bbe8222a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
